Advertisement


Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Welcome and Introduction to Vi3C

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Advertisement